NCT07217184进行中（未招募）1 期
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 20
- 主要终点
- Cohort Expansion (CE) Phase: Overall Response Rate (ORR)
研究概览
简要总结
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 years of age inclusive or older, at the time of signing the informed consent.
- •Participants must have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.
- •Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
- •Participants with a history of autologous stem cell transplant are eligible for study participation when, transplant was >100 days prior to study enrolment and with no active infection(s).
- •Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, unless ECOG less than equal to (<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.
- •Participants with measurable disease defined as at least one of the following: Serum M-protein greater than equal to (>=)0.5 gram per deciliter (>=5 gram per liter) or Urine M-protein >=200 milligrams (mg) per 24 hours or Serum free light chain (FLC) assay: Involved FLC level >=10 mg per deciliter (>=100 mg per Liter) and an abnormal serum FLC ratio (<0.26 or >1.65).
- •Participants who have tested positive for Hepatitis B core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV deoxyribonucleic acid (DNA) undetectable during screening.
- •Participants who are currently receiving physiological doses oral steroids (<10 mg/day), inhaled steroids or ophthalmological steroids.
排除标准
- •Participants with current corneal epithelial disease except mild punctate keratopathy.
- •Participants with evidence of cardiovascular risk.
- •Participants with known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.
- •Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.
- •Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within <14 days.
- •Participants with prior radiotherapy within 2 weeks of start of study therapy.
- •Participants with prior allogeneic transplant are prohibited.
- •Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
- •Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.
- •Participants with prior treatment with an investigational agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.
- •Participants with >=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.
- •Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.
- •Participants must not receive live attenuated vaccines within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.
- •Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.
- •Participants with known human immunodeficiency virus (HIV) infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load<400 copies/milliliter (mL) b) cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >= 350 cells/microliter (µL) c) No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only. For participants receiving nirogacestat, HIV drugs that are strong Cytochrome P450 3A4 (CYP3A4) inhibitors are prohibited. HIV drugs that are moderate CYP3A4 inhibitors, while permitted, should be co-administered with caution and must be accompanied by nirogacestat dose modifications.
- •Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its excipients.
- •Participants with prior treatment with other anti-CD38 monoclonal antibody within 6 months of the first dose of study drug treatment.
- •Participants with known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80.
研究组 & 干预措施
Belantamab mafodotin + Isatuximab
Experimental
干预措施: Isatuximab (Drug)
Belantamab mafodotin + Isatuximab
Experimental
干预措施: Belantamab mafodotin (Drug)
结局指标
主要结局
Cohort Expansion (CE) Phase: Overall Response Rate (ORR)
时间窗: Up to approximately 194 weeks
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Dose Exploration (DE) Phase: Number of participants with dose limiting toxicities (DLTs)
时间窗: Up to 21 days
DE Phase: Number of participants with adverse events (AEs)
时间窗: Up to approximately 194 weeks
DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry, and urinalysis lab parameters
时间窗: Up to approximately 194 weeks
次要结局
- CE Phase: Titre of ADAs against isatuximab(Up to approximately 293 weeks)
- DE Phase: Overall Response Rate(Up to approximately 293 weeks)
- CE Phase: Clinical Benefit Rate (CBR)(Up to approximately 293 weeks)
- DE Phase: Number of participants achieving Partial Response (PR)(Up to approximately 293 weeks)
- CE Phase: Number of participants achieving PR(Up to approximately 293 weeks)
- DE Phase: Number of participants achieving Very Good Partial Response (VGPR)(Up to approximately 293 weeks)
- CE Phase: Number of participants achieving VGPR(Up to approximately 293 weeks)
- DE Phase: Number of participants achieving Complete Response (CR)(Up to approximately 293 weeks)
- CE Phase: Number of participants achieving CR(Up to approximately 293 weeks)
- DE Phase: Number of participants achieving Stringent Complete Response (sCR)(Up to approximately 293 weeks)
- CE Phase: Number of participants achieving sCR(Up to approximately 293 weeks)
- DE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments(Up to approximately 293 weeks)
- CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments(Up to approximately 293 weeks)
- DE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin(Up to approximately 293 weeks)
- CE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin(Up to approximately 293 weeks)
- DE Phase: Number of participants with anti-drug antibodies (ADAs) against belantamab mafodotin(Up to approximately 293 weeks)
- DE Phase: Titre of (ADAs) against belantamab mafodotin(Up to approximately 293 weeks)
- DE Phase: Number of participants with anti-drug antibodies (ADAs) against isatuximab(Up to approximately 293 weeks)
- DE Phase: Titre of (ADAs) against isatuximab(Up to approximately 293 weeks)
- CE Phase: Number of participants with ADAs against belantamab mafodotin(Up to approximately 293 weeks)
- CE Phase: Titre of ADAs against belantamab mafodotin(Up to approximately 293 weeks)
- CE Phase: Number of participants with ADAs against isatuximab(Up to approximately 293 weeks)
- DE Phase: Number of participants with adverse events of special interest (AESI) for belantamab mafodotin(Up to approximately 293 weeks)
- CE Phase: Number of participants with AESI for belantamab mafodotin(Up to approximately 293 weeks)
- DE Phase: Number of participants with AESI for isatuximab(Up to approximately 293 weeks)
- CE Phase: Number of participants with AESI for isatuximab(Up to approximately 293 weeks)
- DE Phase: Number of participants with abnormal ocular findings on ophthalmic examination(Up to approximately 293 weeks)
- CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination(Up to approximately 293 weeks)
- CE Phase: Progression-free survival (PFS)(Up to approximately 293 weeks)
- CE Phase: Duration of response (DoR)(Up to approximately 293 weeks)
- CE Phase: Time to response (TTR)(Up to approximately 293 weeks)
- CE Phase: Overall survival (OS)(Up to approximately 293 weeks)
- CE Phase: Number of participants with AEs and SAEs(Up to approximately 293 weeks)
- CE Phase: Number of participants with AEs leading to discontinuation(Up to approximately 293 weeks)
- CE Phase: Number of participants with AE leading to dose reduction or delay(Up to approximately 293 weeks)
- CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters(Up to approximately 293 weeks)
研究者
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
1 期
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMMultiple MyelomaNCT07217119GlaxoSmithKline25
进行中（未招募）
1 期
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMMultiple MyelomaNCT07150091GlaxoSmithKline20
进行中（未招募）
1 期
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMMultiple MyelomaNCT07150104GlaxoSmithKline14
终止
1 期
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMRelapsed/Refractory Multiple MyelomaNCT06655818GlaxoSmithKline4
终止
1 期
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMMRelapsed/Refractory Multiple MyelomaNCT06160609GlaxoSmithKline9